Clinical trial

Randomized Cross Over Double Blind Versus Placebo Trial Followed by an Open Phase Studying Effect of Norditropin® on Left Ventricular Mass of Growth Hormone Deficient Adult Patients

Name
GHDADULT/F/1/F
Description
This trial is conducted in Europe. The aim of this trial is to assess the effect of somatropin (Norditropin®) replacement therapy on the left ventricular mass of adult patients with a growth hormone deficiency.
Trial arms
Trial start
1998-10-21
Estimated PCD
2002-12-01
Trial end
2002-12-01
Status
Completed
Phase
Early phase I
Treatment
somatropin
Initial dosage 0.5 IU/day, injected subcutaneously (s.c., under the skin) once daily. Dosage will be adjusted monthly depending on clinical safety up to a maximum dose of 3 IU/day. Subjects are treated for six months (randomised trial period) followed by an 12-month open-label trial period with somatropin.
Arms:
Somatropin
placebo
Initial dosage 0.5 IU/day, injected subcutaneously (s.c., under the skin) once daily. Dosage will be adjusted monthly depending on clinical safety up to a maximum dose of 3 IU/day. Subjects are treated for six months. After treatment in the randomised trial period, placebo will be discontinued.
Arms:
Placebo
Size
22
Primary endpoint
Left ventricular mass measured with ultrasonography
Eligibility criteria
Inclusion Criteria: * Childhood or adult onset growth hormone deficiency (GHD) * GHD evidenced by two stimulation tests * Duration of GHD at least 5 years * Other hormone deficiencies associated with growth hormone deficiency Exclusion Criteria: * Pregnancy or pregnancy desired during the suggested duration of the study * Personal history of colonic polyp or family history of colonic polyposis * Known insulin-dependent or non-insulin-dependent diabetes * Cardiovascular disease, left ventricular hypertrophy from other aetiology, recent auricular or ventricular arrhythmia, history of vascularisation by aortocoronary bypass significative mitral or aortic valvular disease, preexcitation syndrome, auriculoventricular conduction delay, bradycardia-tachycardia syndrome, left ventricular mass interfering treatment * BMI (Body Mass Index) at least 30 * Growth hormone treatment during the 24 months prior to inclusion, history of treatment with extractive pituitary growth hormone, allergy or suspected allergy to somatropin therapy * Patient who has participated in a different clinical study within the past two months * Any condition which, in the opinion of the Investigator or the Scientific Committee, may interfere with successful implementation of the study * Notion of breast cancer for the mother or the sister
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'CROSSOVER', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 22, 'type': 'ACTUAL'}}
Updated at
2024-02-28

1 organization

2 products

2 indications

Product
somatropin
Organization
Novo Nordisk
Product
placebo